Virax Biolabs Group Limited
VRAX · NASDAQ
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 16.7% | -72.2% | -93.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -13,396.4% | -3,381.2% | -130.7% | 50.1% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $2 | $2 | $2 |
| SG&A Expenses | $1 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $4 |
| Operating Income | -$3 | -$3 | -$3 | -$4 |
| % Margin | -160,788.2% | -238,316.8% | -58,124.2% | -4,742.6% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$3 | -$3 | -$3 | -$4 |
| Tax Expense | -$0 | $0 | -$0 | $0 |
| Net Income | -$2 | -$3 | -$3 | -$4 |
| % Margin | -145,446% | -239,827.3% | -55,651.7% | -4,784.7% |
| EPS | -0.49 | -0.76 | -0.89 | -1.71 |
| % Growth | 35.5% | 14.6% | 48% | – |
| EPS Diluted | -0.49 | -0.76 | -0.89 | -1.71 |
| Weighted Avg Shares Out | 5 | 4 | 3 | 2 |
| Weighted Avg Shares Out Dil | 5 | 4 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$3 | -$4 |
| % Margin | -147,336.7% | -227,823.3% | -55,861.2% | -4,658.2% |